Refocusing Tarveda on tumor-targeted mini-drug conjugates

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized drug conjugates, designed to target, penetrate and eradicate solid tumors. Having raised USD 38 million early in 2016 to execute the plan, Tarveda president, CEO and interim chairman, Drew Fromkin, explains to Mike Ward, Informa Pharma Intelligence insights global director of content, what progress has been made and what milestones are on the horizon.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Drew Fromkin – President, CEO and Interim Chairman, Tarveda Therapeutics